Vertex Pharmaceuticals (Europe) Ltd
An insider at 1 company in coverage, as reported on Form 4. SEC CIK 1761216. Latest Form 4 filed Dec 28, 2018.
Roles
As stated on the filings: the relationship to the company and any officer title.
| Company | Role | Transactions | First | Latest |
|---|---|---|---|---|
| CRISPR Therapeutics AGCRSP | 10% owner | 6 | 2018-12-21 | 2018-12-27 |
Transactions: 6
Every transaction reported, newest first, including grants, exercises and derivative securities. Purchases and sales (codes P and S) are open-market trades. The reported price is as stated on the form.
What these mean: insiders, Form 4, transaction codes, Rule 10b5-1 plans.
| Date | Company | Transaction | Shares | Reported price | Value | Filing |
|---|---|---|---|---|---|---|
| 2018-12-27 | CRISPR Therapeutics AG10% owner | Purchase | 27,461 | $24.9487 | $685.1k | Form 4 |
| 2018-12-26 | CRISPR Therapeutics AG10% owner | Purchase | 12,737 | $24.8942 | $317.1k | Form 4 |
| 2018-12-24 | CRISPR Therapeutics AG10% owner | Purchase | 53,655 | $24.9687 | $1.3m | Form 4 |
| 2018-12-24 | CRISPR Therapeutics AG10% owner | Purchase | 11,742 | $23.1766 | $272.1k | Form 4 |
| 2018-12-24 | CRISPR Therapeutics AG10% owner | Purchase | 2,603 | $22.9147 | $59.6k | Form 4 |
| 2018-12-21 | CRISPR Therapeutics AG10% owner | Purchase | 22,742 | $22.5784 | $513.5k | Form 4 |
Source: SEC EDGAR, Forms 4. Last ingested by Listed: Nov 2, 2026, 17:10 ET. Listed shows no prices and gives no investment advice.